Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Young发布了新的文献求助10
1秒前
华仔应助李嘉琪采纳,获得10
2秒前
兆渊完成签到,获得积分10
2秒前
洁净的慕山完成签到 ,获得积分10
2秒前
SciGPT应助杪杪采纳,获得10
3秒前
丘比特应助ttt采纳,获得10
8秒前
8秒前
10秒前
糊涂的觅海完成签到 ,获得积分10
10秒前
zfm完成签到,获得积分10
12秒前
可爱的函函应助ruby采纳,获得30
12秒前
燕子发布了新的文献求助30
13秒前
Jasper应助木鱼采纳,获得10
14秒前
杨咩咩发布了新的文献求助30
14秒前
14秒前
Kao应助sxk采纳,获得10
15秒前
阳光迎夏完成签到 ,获得积分10
15秒前
16秒前
16秒前
16秒前
bkagyin应助lisn采纳,获得10
17秒前
流白发布了新的文献求助10
18秒前
luckytree完成签到,获得积分10
19秒前
领导范儿应助zxyx4j采纳,获得10
19秒前
Young完成签到,获得积分10
20秒前
21秒前
彭于晏应助em采纳,获得10
21秒前
shengwufenzi发布了新的文献求助10
22秒前
壮观白筠完成签到 ,获得积分10
22秒前
巴山郎发布了新的文献求助10
22秒前
任志政完成签到 ,获得积分10
24秒前
Bin完成签到,获得积分10
24秒前
科研通AI6.4应助流白采纳,获得10
25秒前
25秒前
龙建香发布了新的文献求助20
25秒前
ruby发布了新的文献求助30
26秒前
FCF完成签到 ,获得积分10
26秒前
李垣锦完成签到 ,获得积分10
27秒前
29秒前
lisn完成签到,获得积分10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Markov Chain Monte Carlo 5000
《上海道教》季刊 2200
Evidence Summary. Injection (subcutaneous):op- timal administration 1000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
Curating Socialism: A Handbook of International Art Exhibitions 1947-1989 530
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7486198
求助须知:如何正确求助?哪些是违规求助? 9078177
关于积分的说明 19360276
捐赠科研通 7100642
什么是DOI,文献DOI怎么找? 3248356
关于科研通互助平台的介绍 2417666
邀请新用户注册赠送积分活动 2233782